Literature DB >> 28028715

Study on the Intervention Effects of Pinggan Prescription () on Spontaneously Hypertensive Rats Based on Metabonomic and Pharmacodynamic Methods.

Jun Xie1,2, Hai-Qiang Jiang3, Yun-Lun Li4, Lei Nie5, Hong-Lei Zhou3, Wen-Qing Yang3.   

Abstract

OBJECTIVE: To investigate the effects of Pinggan Prescription (, PGP) on hypertension by the associated methods of metabonomic and pharmacodynamic.
METHODS: A total of 32 male spontaneously hypertensive rats (SHRs) were randomly divided into two groups by using the random number table method: a treatment group (n=18) and a model group (n=14). The Wistar rats (n=14) were used as the normal group. Different prescription were used to intervene three groups: the treatment group in which PGP extract was administered orally at a dose of 18.336 g/kg (PGP/body weight), and the model group in which physiological saline was administered at the equivalent dose. The same treatment was applied to the normal group as the model group. The blood pressure was measured by tail-cuff method, and pharmacodynamic indexes including cyclic adenosine monophosphate (cAMP) and angiotensin II (Ang II) were tested by enzyme-linked immunosorbent assay. The plasma samples from three groups were detected by gas chromatography-mass spectrometry (GC-MS).
RESULTS: Compared with the model group, blood pressure of treatment group was obviously reduced after continuous curing with PGP (P<0.01). The pharmacodynamic results illustrated that the content of Ang II increased with the raised blood pressure and the cAMP expressed the converse trend. After curing with PGP, the content of Ang II decreased, the difference between model group and treatment group was significant (P<0.01), and the cAMP expressed the converse trend. Five potential biomarkers were identified, including arachidonic acid, hexadecanoic acid, elaidic acid, octadecanedioic acid and 9,12-octadecadienoic acid. These metabolites had shown significantly changes as followed: arachidonic acid, hexadecanoic acid and elaidic acid were significantly higher and octadecanedioic acid and 9,12-octadecadienoic acid were lowered in the model group than those in the normal group. After the treatment of PGP, the metabolites had the trends of returning to normal along with the reduced blood pressure.
CONCLUSIONS: PGP intervention for hypertension played a major role in the metabolism of arachidonic acid and linoleic acid. Metabonomic with pharmacodynamic methods could be potentially powerful tools to investigate the mechanism of Chinese medicine.

Entities:  

Keywords:  Chinese medicine; Pinggan Prescription; hypertension; metabonomic; pharmacodynamic

Mesh:

Substances:

Year:  2016        PMID: 28028715     DOI: 10.1007/s11655-015-2126-1

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  4 in total

1.  Application and Prospect of Platelet Multi-Omics Technology in Study of Blood Stasis Syndrome.

Authors:  Ying Li; Ming-Qian Sun; Lei Li; Ye-Hao Zhang; Lan Miao; Jian-Xun Liu
Journal:  Chin J Integr Med       Date:  2021-12-20       Impact factor: 1.978

2.  Common Metabolites in Two Different Hypertensive Mouse Models: A Serum and Urine Metabolome Study.

Authors:  Gaurav Baranwal; Rachel Pilla; Bethany L Goodlett; Aja K Coleman; Cristina M Arenaz; Arul Jayaraman; Joseph M Rutkowski; Robert C Alaniz; Brett M Mitchell
Journal:  Biomolecules       Date:  2021-09-21

3.  LC-MS-based lipidomic analysis of liver tissue sample from spontaneously hypertensive rats treated with extract hawthorn fruits.

Authors:  Luping Sun; Bingqing Chi; Mingfeng Xia; Zhen Ma; Hongbin Zhang; Haiqiang Jiang; Fang Zhang; Zhenhua Tian
Journal:  Front Pharmacol       Date:  2022-08-09       Impact factor: 5.988

4.  Antihypertensive activity of oleanolic acid is mediated via downregulation of secretory phospholipase A2 and fatty acid synthase in spontaneously hypertensive rats.

Authors:  Shiming Zhang; Yuecheng Liu; Xiaoming Wang; Zhenhua Tian; Dongmei Qi; Yunlun Li; Haiqiang Jiang
Journal:  Int J Mol Med       Date:  2020-09-30       Impact factor: 4.101

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.